



September 8th, 2017 • 8:30am-2:30pm
PCAM South • "B" Elevator • Floor 14 • Room 101

8:30 am Breakfast

9:00 am Welcome and Introduction
Corey J. Langer, MD
(Co-Director of Thoracic Lung TCE)

SESSION 1: TUMOR VACCINES AND OTHER IMMUNOMODULATING STRATEGIES

9:05 am **Robert Vonderheide, MD, DPhil**
TCE Overview and hTERT DNA Immunotherapy Trial in Adults with Lung Cancer

9:20 am **Corey J. Langer, MD**
Overview of Clinical Aspects of TCE: Ongoing and Completed Studies at the University of Pennsylvania's Abramson Cancer Center

9:30 am **Charu Aggarwal, MD**
Adenoviral Vector Expressing Herpes Thymidine Kinase (AdV-tk) Gene for Patients with Thoracic Malignancies

9:40 am **Jarrold D. Predina, MD**
Intratumoral Neoadjuvant AdV-tk for Patients with High Risk Resectable Lung Cancer

9:50 am **Evan W. Alley, MD, PhD**
Emerging Therapies in Malignant Pleural Mesothelioma: Insights from our Multidisciplinary Pleural Tumor Center

10:00 am Coffee Break

SESSION 2: NOVEL APPROACHES AND CHECKPOINT INHIBITORS IN CLINICAL TRIALS

10:10 am **Corey J. Langer, MD**
Recently Completed Checkpoint Inhibitor Trials in 1st and 2nd Line Non-small Cell Lung Cancer (NSCLC) at the University of Pennsylvania's Abramson Cancer Center

10:20 am **Stephen J. Bagley, MD**
Pretreatment Neutrophil-to-Lymphocyte Ratio as a Marker of Outcomes: Insights from our 1st Year's Experience with Nivolumab in 2nd Line and Beyond in Advanced NSCLC

10:30 am **Corey J. Langer, MD** (On Behalf of Joshua M. Bauml, MD)
Phase II Study of Pembrolizumab after Curative Intent Treatment for Oligometastatic NSCLC

10:40 am **Christine M. Ciunci, MD**
Phase II Trial of Consolidation Pembrolizumab after Concurrent Chemotherapy and Proton Re-irradiation for Thoracic Recurrences of NSCLC

10:50 am **Guest Speaker: Martin J. Edelman, MD**
Chair, Dept. of Heme/Onc, FCCC)
Current Translational and Clinical Research Initiatives at Fox Chase Cancer Center

SESSION 3: DATA CAPTURE FOR CANCER RESEARCH AND TRANSLATIONAL MEDICINE

11:10 am **Christiana W. Davis, MD**
(Project/Database Manager of Thoracic Lung TCE)
The State of Thoracic TCE Databases: Insights from a Retrospective Analysis of Epidermal Growth Factor Receptor and the Tumor Suppressor TP53 Genes in NSCLC Patients

11:20 am **Michael D. Feldman, MD, PhD**
Text Information Extraction System (TIES)-A Clinical Document Search Engine that Supports Tissue Ordering and Acquisition, Building of Tissue Microarrays, and Integration with Tissue Banks

11:35 am **Peter Gabriel, MD**
Abramson Cancer Center Strategy for Disease-Specific Research Registries

11:50 am Lunch

SESSION 4: NOVEL BIOMARKERS AND RADIOLOGIC CORRELATIVES TO PREDICT RESPONSE TO IMMUNOTHERAPY

12:20 pm **E. John Wherry, PhD**
Emerging Biocorrelatives in Predicting Benefits to Immuno-Oncology Treatment

12:35 pm **Alexander Huang, MD**
Re-invigoration of Exhausted CD8 T Cells in NSCLC

12:45 pm **Erica L. Carpenter, MBA, PhD**
Liquid Biopsy for Diagnosis and Monitoring of Lung Cancer

12:55 pm **Jeffrey Thompson, MD**
The Clinical Utility of a Circulating Tumor DNA Next Generation Sequencing (NGS) Panel of Oncogenic and Tumor Suppressor Genes in NSCLC Patients

1:05 pm **Jennifer J.D. Morrissette, PhD**
Genomic Alterations in Lung Tumors: Mutational Landscape and Translocation Detection by NGS

1:15 pm **Edmund Moon, MD**
A Pilot Study to Determine the Feasibility of Utilizing Fine Needle Aspirates to Perform In-depth Immune Profiling of Lung Cancer

1:25 pm **Sharyn Katz, MD**
Role of Positron Emission Tomography Imaging in Predicting Benefits to Immunotherapy

SESSION 5: CAR T CELL AND OTHER IMMUNOCONJUGATE TREATMENT STRATEGIES

1:35 pm **Andrew R. Haas, MD**
Chimeric Antigen Receptor (CAR) T-Cells Targeting Mesothelin for Malignant Pleural Mesothelioma

1:45 pm **Charu Aggarwal, MD**
CAR T Cells Targeting Mesothelin for Lung Cancer

1:55 pm **Corey J. Langer, MD**
Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

SESSION 6: OTHER INITIATIVES IN LUNG CANCER

2:05 pm **Anil Vachani, MD**
Initiatives to Expedite the Evaluation and Treatment of Lung Nodules

2:15 pm **Steven M. Albelda, MD**
New Oncology Research Alliance between UPenn and Industry

2:25 pm Closing Remarks – Feedback
Corey J. Langer, MD